Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

111 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Recurrent/Metastatic Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Heading?
Juarez-Vignon Whaley JJ, Afkhami M, Onyshchenko M, Massarelli E, Sampath S, Amini A, Bell D, Villaflor VM. Juarez-Vignon Whaley JJ, et al. Among authors: massarelli e. Curr Treat Options Oncol. 2023 Sep;24(9):1138-1166. doi: 10.1007/s11864-023-01101-3. Epub 2023 Jun 15. Curr Treat Options Oncol. 2023. PMID: 37318724 Free PMC article. Review.
Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells.
Tang C, Welsh JW, de Groot P, Massarelli E, Chang JY, Hess KR, Basu S, Curran MA, Cabanillas ME, Subbiah V, Fu S, Tsimberidou AM, Karp D, Gomez DR, Diab A, Komaki R, Heymach JV, Sharma P, Naing A, Hong DS. Tang C, et al. Among authors: massarelli e. Clin Cancer Res. 2017 Mar 15;23(6):1388-1396. doi: 10.1158/1078-0432.CCR-16-1432. Epub 2016 Sep 20. Clin Cancer Res. 2017. PMID: 27649551 Free PMC article. Clinical Trial.
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer.
De Laurentiis M, Arpino G, Massarelli E, Ruggiero A, Carlomagno C, Ciardiello F, Tortora G, D'Agostino D, Caputo F, Cancello G, Montagna E, Malorni L, Zinno L, Lauria R, Bianco AR, De Placido S. De Laurentiis M, et al. Among authors: massarelli e. Clin Cancer Res. 2005 Jul 1;11(13):4741-8. doi: 10.1158/1078-0432.CCR-04-2569. Clin Cancer Res. 2005. PMID: 16000569 Free article.
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
Pfister DG, Haddad RI, Worden FP, Weiss J, Mehra R, Chow LQM, Liu SV, Kang H, Saba NF, Wirth LJ, Sukari A, Massarelli E, Ayers M, Albright A, Webber AL, Mogg R, Lunceford J, Huang L, Cristescu R, Cheng J, Seiwert TY, Bauml JM. Pfister DG, et al. Among authors: massarelli e. Cancer Med. 2023 Mar;12(6):6603-6614. doi: 10.1002/cam4.5434. Epub 2022 Dec 7. Cancer Med. 2023. PMID: 36479637 Free PMC article.
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung.
Leighl NB, Raez LE, Besse B, Rosen PJ, Barlesi F, Massarelli E, Gabrail N, Hart LL, Albain KS, Berkowitz L, Melnyk O, Shepherd FA, Sternas L, Ackerman J, Shun Z, Miller VA, Herbst RS. Leighl NB, et al. Among authors: massarelli e. J Thorac Oncol. 2010 Jul;5(7):1054-9. doi: 10.1097/jto.0b013e3181e2f7fb. J Thorac Oncol. 2010. PMID: 20593550 Free article. Clinical Trial.
Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA Jr, Ro JY, Ordonez NG, Tran HT, Yang Y, Smith TL, Mass RD, Herbst RS. Zinner RG, et al. Among authors: massarelli e. Lung Cancer. 2004 Apr;44(1):99-110. doi: 10.1016/j.lungcan.2003.09.026. Lung Cancer. 2004. PMID: 15013588 Clinical Trial.
111 results